Skip to main content
Erschienen in: Current Infectious Disease Reports 5/2011

01.10.2011

Antibiotic Therapy in Neonatal and Pediatric Septic Shock

verfasst von: Rajesh K. Aneja, Ruby Varughese-Aneja, Carol G. Vetterly, Joseph A. Carcillo

Erschienen in: Current Infectious Disease Reports | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Severe sepsis accounts for nearly 4,500 deaths (mortality rate 10%), and is responsible for nearly $2 billion annual healthcare expenditure in the United States. Early and speedy treatment of critically ill septic patients can halt or reduce the likelihood of physiologic progression to multi-system organ failure. A cornerstone of this therapeutic strategy is antibiotic administration. In this review, we discuss the empirical treatment strategies for the treatment of early and late neonatal sepsis, along with pediatric sepsis. Furthermore, we discuss the rationale that underlies the adoption of such treatment strategies. The present article also discusses the emergence of multi-drug organisms as the causative agents for sepsis, i.e. methicillin-resistant Staphylococcus aureus (MRSA), resistant enterococci and Klebsiella pneumoniae carbapenemases (KPC).
Literatur
1.
Zurück zum Zitat Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med. 2005;6(3 Suppl):S3–5.PubMedCrossRef Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med. 2005;6(3 Suppl):S3–5.PubMedCrossRef
2.
Zurück zum Zitat Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef
3.
Zurück zum Zitat Hartman M, Clermont G, Angus D, Watson R. Pediatric severe sepsis in the US: 1995 vs. 2005. Crit Care Med. 2008;36:A76. Hartman M, Clermont G, Angus D, Watson R. Pediatric severe sepsis in the US: 1995 vs. 2005. Crit Care Med. 2008;36:A76.
4.
Zurück zum Zitat Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167(5):695–701.PubMedCrossRef
5.
Zurück zum Zitat •• Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666–88. A must read for all pediatricians, as these are the guidelines for pediatric and neonatal septic shock.PubMedCrossRef •• Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666–88. A must read for all pediatricians, as these are the guidelines for pediatric and neonatal septic shock.PubMedCrossRef
6.
Zurück zum Zitat • Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96. An important article that highlights the role of timely administration of antibiotics. PubMedCrossRef • Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96. An important article that highlights the role of timely administration of antibiotics. PubMedCrossRef
7.
Zurück zum Zitat Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38(4):1045–53.PubMedCrossRef Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38(4):1045–53.PubMedCrossRef
8.
Zurück zum Zitat Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F4–8.PubMedCrossRef Muller-Pebody B, Johnson AP, Heath PT, et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F4–8.PubMedCrossRef
9.
Zurück zum Zitat Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2006;(1):CD005091. Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2006;(1):CD005091.
10.
Zurück zum Zitat Edwards M, Baker C. In: Long S, Pickering L, Prober C, editors. Bacterial infections in the neonate. Philadelphia: Churchill Livingstone; 2002. Edwards M, Baker C. In: Long S, Pickering L, Prober C, editors. Bacterial infections in the neonate. Philadelphia: Churchill Livingstone; 2002.
11.
Zurück zum Zitat • Vergnano S, Menson E, Kennea N, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F9–14. This is a prospective multi-center surveillance study that was conducted in 12 English neonatal units. PubMedCrossRef • Vergnano S, Menson E, Kennea N, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F9–14. This is a prospective multi-center surveillance study that was conducted in 12 English neonatal units. PubMedCrossRef
12.
Zurück zum Zitat Bryan CS, John Jr JF, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child. 1985;139(11):1086–9.PubMed Bryan CS, John Jr JF, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child. 1985;139(11):1086–9.PubMed
13.
Zurück zum Zitat de Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355(9208):973–8.PubMedCrossRef de Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355(9208):973–8.PubMedCrossRef
14.
Zurück zum Zitat Modi N, Damjanovic V, Cooke RW. Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit. Arch Dis Child. 1987;62(2):148–51.PubMedCrossRef Modi N, Damjanovic V, Cooke RW. Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit. Arch Dis Child. 1987;62(2):148–51.PubMedCrossRef
15.
Zurück zum Zitat Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics. 2006;117(1):67–74.PubMedCrossRef Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics. 2006;117(1):67–74.PubMedCrossRef
16.
Zurück zum Zitat Auriti C, Maccallini A, Di Liso G, et al. Risk factors for nosocomial infections in a neonatal intensive-care unit. J Hosp Infect. 2003;53(1):25–30.PubMedCrossRef Auriti C, Maccallini A, Di Liso G, et al. Risk factors for nosocomial infections in a neonatal intensive-care unit. J Hosp Infect. 2003;53(1):25–30.PubMedCrossRef
17.
Zurück zum Zitat Orsi G, d’Ettorre G, Panero A, et al. Hospital-acquired infection surveillance in a neonatal intensive care unit. Am J Infect Control. 2009;37:201–3.PubMedCrossRef Orsi G, d’Ettorre G, Panero A, et al. Hospital-acquired infection surveillance in a neonatal intensive care unit. Am J Infect Control. 2009;37:201–3.PubMedCrossRef
18.
Zurück zum Zitat Tan T, Mason E, Ou C, Kaplan S. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993;37:2401–6.PubMed Tan T, Mason E, Ou C, Kaplan S. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993;37:2401–6.PubMed
19.
Zurück zum Zitat Wu J, Chen C, Tsao P, et al. Neonatal sepsis: a 6-year analysis in a neonatal care unit in Taiwan. Pediatr Neonatol. 2009;50:88–95.PubMedCrossRef Wu J, Chen C, Tsao P, et al. Neonatal sepsis: a 6-year analysis in a neonatal care unit in Taiwan. Pediatr Neonatol. 2009;50:88–95.PubMedCrossRef
20.
Zurück zum Zitat Khashu M, Osiovich H, Henry D, et al. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit. Pediatrics. 2006;117(2):340–8.PubMedCrossRef Khashu M, Osiovich H, Henry D, et al. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit. Pediatrics. 2006;117(2):340–8.PubMedCrossRef
21.
Zurück zum Zitat Archer GL, Tenenbaum MJ, Haywood 3rd HB. Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA. 1978;240(8):751–3.PubMedCrossRef Archer GL, Tenenbaum MJ, Haywood 3rd HB. Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices. JAMA. 1978;240(8):751–3.PubMedCrossRef
22.
Zurück zum Zitat Auger P, Laaban JP, Gagnon G, et al. Rifampin therapy for Staphylococcus epidermidis endocarditis. Can Med Assoc J. 1982;127(7):609–10.PubMed Auger P, Laaban JP, Gagnon G, et al. Rifampin therapy for Staphylococcus epidermidis endocarditis. Can Med Assoc J. 1982;127(7):609–10.PubMed
23.
Zurück zum Zitat Chamovitz B, Bryant RE, Gilbert DN, Hartstein AI. Prosthetic valve endocarditis caused by Staphylococcus epidermidis. Development of rifampin resistance during vancomycin and rifampin therapy. JAMA. 1985;253(19):2867–8.PubMedCrossRef Chamovitz B, Bryant RE, Gilbert DN, Hartstein AI. Prosthetic valve endocarditis caused by Staphylococcus epidermidis. Development of rifampin resistance during vancomycin and rifampin therapy. JAMA. 1985;253(19):2867–8.PubMedCrossRef
24.
Zurück zum Zitat Isaacs D. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed. 2003;88(2):F89–93.PubMedCrossRef Isaacs D. A ten year, multicentre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed. 2003;88(2):F89–93.PubMedCrossRef
25.
Zurück zum Zitat Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988–1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106(6):1387–90.PubMedCrossRef Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988–1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106(6):1387–90.PubMedCrossRef
26.
Zurück zum Zitat Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285–91.PubMedCrossRef Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285–91.PubMedCrossRef
27.
Zurück zum Zitat Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: 1992–2002. Pediatr Infect Dis J. 2006;25(1):25–9.PubMedCrossRef Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: 1992–2002. Pediatr Infect Dis J. 2006;25(1):25–9.PubMedCrossRef
28.
Zurück zum Zitat Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med. 2003;4(3):333–7.PubMedCrossRef Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med. 2003;4(3):333–7.PubMedCrossRef
29.
Zurück zum Zitat Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children’s Hospital. Arch Pediatr Adolesc Med. 2005;159(10):980–5.PubMedCrossRef Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children’s Hospital. Arch Pediatr Adolesc Med. 2005;159(10):980–5.PubMedCrossRef
30.
Zurück zum Zitat Ochoa TJ, Mohr J, Wanger A, et al. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis. 2005;11(6):966–8.PubMed Ochoa TJ, Mohr J, Wanger A, et al. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis. 2005;11(6):966–8.PubMed
31.
Zurück zum Zitat Smith JM, Cook GM. A decade of community MRSA in New Zealand. Epidemiol Infect. 2005;133(5):899–904.PubMedCrossRef Smith JM, Cook GM. A decade of community MRSA in New Zealand. Epidemiol Infect. 2005;133(5):899–904.PubMedCrossRef
32.
Zurück zum Zitat Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–74.PubMedCrossRef Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–74.PubMedCrossRef
33.
Zurück zum Zitat Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2006;87(1):3–9.PubMedCrossRef Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2006;87(1):3–9.PubMedCrossRef
34.
Zurück zum Zitat Panton P, Came M, Valentine F. Staphylococcal toxin. Lancet. 1932;1:506–8.CrossRef Panton P, Came M, Valentine F. Staphylococcal toxin. Lancet. 1932;1:506–8.CrossRef
35.
Zurück zum Zitat Prevost G, Cribier B, Couppie P, et al. Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun. 1995;63(10):4121–9.PubMed Prevost G, Cribier B, Couppie P, et al. Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun. 1995;63(10):4121–9.PubMed
36.
Zurück zum Zitat Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001–2003. Pediatr Infect Dis J. 2006;25(4):343–8.PubMedCrossRef Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001–2003. Pediatr Infect Dis J. 2006;25(4):343–8.PubMedCrossRef
37.
Zurück zum Zitat Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753–9.PubMedCrossRef Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753–9.PubMedCrossRef
38.
Zurück zum Zitat Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353(12):1245–51.PubMedCrossRef Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353(12):1245–51.PubMedCrossRef
39.
Zurück zum Zitat Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis. 2003;37(8):1050–8.PubMedCrossRef Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis. 2003;37(8):1050–8.PubMedCrossRef
40.
Zurück zum Zitat Gillet Y, Etienne J, Lina G, Vandenesch F. Association of necrotizing pneumonia with Panton-Valentine leukocidin-producing Staphylococcus aureus, regardless of methicillin resistance. Clin Infect Dis. 2008;47(7):985–6.PubMedCrossRef Gillet Y, Etienne J, Lina G, Vandenesch F. Association of necrotizing pneumonia with Panton-Valentine leukocidin-producing Staphylococcus aureus, regardless of methicillin resistance. Clin Infect Dis. 2008;47(7):985–6.PubMedCrossRef
41.
Zurück zum Zitat Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.PubMedCrossRef Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.PubMedCrossRef
42.
Zurück zum Zitat Martinez-Aguilar G, Hammerman WA, Mason Jr EO, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22(7):593–8.PubMed Martinez-Aguilar G, Hammerman WA, Mason Jr EO, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22(7):593–8.PubMed
43.
Zurück zum Zitat Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S178–85.PubMed Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S178–85.PubMed
44.
Zurück zum Zitat Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis. 2005;37(2):153–4.PubMedCrossRef Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis. 2005;37(2):153–4.PubMedCrossRef
45.
Zurück zum Zitat National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–85. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–85.
46.
47.
Zurück zum Zitat Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin. 2011;27(1):163–205.PubMedCrossRef Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin. 2011;27(1):163–205.PubMedCrossRef
48.
Zurück zum Zitat Sullivan J, Tobias JD. Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit. Am J Ther. 2006;13(6):473–7.PubMed Sullivan J, Tobias JD. Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit. Am J Ther. 2006;13(6):473–7.PubMed
49.
Zurück zum Zitat Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–9.PubMedCrossRef Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–9.PubMedCrossRef
50.
Zurück zum Zitat Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–61.PubMedCrossRef Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–61.PubMedCrossRef
51.
Zurück zum Zitat Maltezou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58(3):213–9.PubMedCrossRef Maltezou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect. 2009;58(3):213–9.PubMedCrossRef
52.
Zurück zum Zitat Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56(1):128–32.PubMedCrossRef Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56(1):128–32.PubMedCrossRef
53.
Zurück zum Zitat •• Overturf GD. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J. 2010;29(1):68–70. An excellent review of Carbapenemases.PubMed •• Overturf GD. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J. 2010;29(1):68–70. An excellent review of Carbapenemases.PubMed
Metadaten
Titel
Antibiotic Therapy in Neonatal and Pediatric Septic Shock
verfasst von
Rajesh K. Aneja
Ruby Varughese-Aneja
Carol G. Vetterly
Joseph A. Carcillo
Publikationsdatum
01.10.2011
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 5/2011
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-011-0197-5

Weitere Artikel der Ausgabe 5/2011

Current Infectious Disease Reports 5/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.